Skip to main content

Market Overview

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Share:
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • D. Boral Capital analyst Jason Kolbert initiated coverage on NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) with a Buy rating and announced a price target of $14. NeuroSense Therapeutics shares closed at $1.0438 on Friday. See how other analysts view this stock.
  • Maxim Group analyst Jason McCarthy initiated coverage on ProMIS Neurosciences, Inc. (NASDAQ:PMN) with a Buy rating and announced a price target of $3. ProMIS Neurosciences shares closed at $0.5020 on Friday. See how other analysts view this stock.
  • Maxim Group initiated coverage on Primis Financial Corp. (NASDAQ:FRST) with a Buy rating and announced a price target of $1. Primis Finl shares closed at $8.96 on Friday. See how other analysts view this stock.

Considering buying NRSN stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

 

Related Articles (FRST + NRSN)

View Comments and Join the Discussion!

Posted-In: Top InitiationsNews Initiation Markets Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com